Drug Trial Radar · NCT01288378
Empirical Versus Preemptive Antifungal Therapy
Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
556
Actual
Start
Mar 2012
Primary completion
Apr 4, 2019
Study completion Apr 4, 2019
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- First posted
- Feb 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their cancer. It is not yet known whether caspofungin acetate is more effective when treatment starts after development of a fever or after the infection is shown in laboratory test, chest x-ray, or CT scan. PURPOSE: This randomized phase III trial is studying the best time to start caspofungin acetate therapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome that is newly diagnosed or in first relapse.
Conditions
- Fungal Infection
- Leukemia
- Myelodysplastic Syndromes
Interventions
caspofungin acetateDrug
intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival at 42 days after randomizationTime frame: 6 weeks after randomization
Locations
16 sites in 6 countries. Site status is shown where the registry gives one.
A.Z. St. Jan
Bruges, Belgium
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Hôpitaux Universitaires Bordet-Erasme - Institut Jules Bordet
Brussels, Belgium
U.Z. Gasthuisberg
Leuven, Belgium
C.H.U. Sart-Tilman
Liège, Belgium
Masaryk University
Brno, Czechia
CHU de Caen - Hopital Cote de Nacre
Caen, France
C.H.U. Henri Mondor AP-HP
Créteil, France
CHRU de Lille - Hopital Hurie
Lille, France
CHU de Limoges - Hopital Dupuytren
Limoges, France
Hopital Universitaire Hautepierre
Strasbourg, France
Institut Gustave Roussy
Villejuif, France
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany
Universitaetsklinikum Wuerzburg - Medizinische Klinik und Poliklinik II
Würzburg, Germany
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands
National Cancer Institute
Bratislava, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.